IL6 and COVID-19: SSRIs decreased plasma levels of four of 16 tested inflammatory mediators, including interleukin (IL)-10, tumor necrosis factor (TNF)-α, and CCL-2, which are associated with COVID-19 severity (Lee and Giuliani, 2019; Hojyo et al., 2020), and IL-6, which highly plays a role in disease mortality (Aziz et al., 2020; Hojyo et al., 2020; McElvaney et al., 2020; Tay et al., 2020; Ye et al., 2020).